944896-44-0

Usage

Uses

Used in Pharmaceutical Industry:
6-methoxyimidazo[1,2-a]pyridine-3-carboxylic acid is used as a drug candidate for its potential therapeutic effects on various conditions. 6-methoxyimidazo[1,2-a]pyridine-3-carboxylic acid's anti-inflammatory and anti-tumor properties make it suitable for the development of medications targeting inflammation, cancer, and neurological disorders.
Used in Anti-inflammatory Applications:
6-methoxyimidazo[1,2-a]pyridine-3-carboxylic acid is used as an anti-inflammatory agent, leveraging its ability to modulate inflammatory pathways and reduce inflammation-related symptoms. Its potential use in treating conditions with an inflammatory component highlights its value in this application.
Used in Anticancer Applications:
6-methoxyimidazo[1,2-a]pyridine-3-carboxylic acid is used as an anticancer agent, where its properties may contribute to the inhibition of tumor growth and the modulation of cancer-related signaling pathways. 6-methoxyimidazo[1,2-a]pyridine-3-carboxylic acid's potential to be developed into a chemotherapeutic agent is under investigation for its efficacy against various types of cancer.
Used in Neurological Disorder Treatment:
6-methoxyimidazo[1,2-a]pyridine-3-carboxylic acid is used as a potential treatment for neurological disorders, given its capacity to interact with neurological pathways and potentially alleviate symptoms associated with such conditions. Its role in the development of neuroprotective or symptomatic relief medications is an area of ongoing research.

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds of formulae (I) and (II) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRcalpha PDGFRbeta) kinases